Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma

This phase I study utilizes a 3+3 design with escalating cohorts of Carfilzomib at 20mg/m2, 27mg/m2, 36mg/m2, 45mg/m2, 56mg/m2, and 70mg/m2 to be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone and Granulocyte colony-stimulating factor (G-CSF)

Trial Details

NCT ID
NCT03909412
Phase
PHASE1
Sponsor
Hackensack Meridian Health
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Carfilzomib
  • Cyclophosphamide
  • Dexamethasone
  • Granulocyte Colony-Stimulating Factor
Locations (sample)
  • Hackensack, New Jersey, United States|40.88593,-74.04347

Key Eligibility Criteria

  • Subject has a confirmed diagnosis of multiple myeloma as specified by the International Myeloma Working Group criteria and must have measurable dis…
  • Serum monoclonal protein ≥ 0.5 g/dL
  • ≥200 mg of monoclonal protein in the urine on 24-hour electrophoresis
  • Serum immunoglobulin free light chain: involved FLC ≥ 10 mg/dL (≥ 100 mg/L) AND abnormal serum immunoglobulin kappa to lambda free light chain ratio

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →